mebendazole has been researched along with Carcinoma, Hepatocellular in 3 studies
Mebendazole: A benzimidazole that acts by interfering with CARBOHYDRATE METABOLISM and inhibiting polymerization of MICROTUBULES.
mebendazole : A carbamate ester that is methyl 1H-benzimidazol-2-ylcarbamate substituted by a benzoyl group at position 5.
Carcinoma, Hepatocellular: A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sorafenib (SO) is a multi-kinase inhibitor that targets upstream signals in the MAPK pathway." | 5.51 | Mebendazole augments sensitivity to sorafenib by targeting MAPK and BCL-2 signalling in n-nitrosodiethylamine-induced murine hepatocellular carcinoma. ( Ghanim, AMH; Saber, S; Younis, NS, 2019) |
| "Sorafenib (SO) is a multi-kinase inhibitor that targets upstream signals in the MAPK pathway." | 1.51 | Mebendazole augments sensitivity to sorafenib by targeting MAPK and BCL-2 signalling in n-nitrosodiethylamine-induced murine hepatocellular carcinoma. ( Ghanim, AMH; Saber, S; Younis, NS, 2019) |
| "Mebendazole treatment was begun." | 1.36 | [Hepatocellular carcinoma complicated with echinococcal cyst of the liver]. ( Dragnev, N; Kobakov, G; Kostov, D; Patanov, R, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Younis, NS | 1 |
| Ghanim, AMH | 1 |
| Saber, S | 1 |
| Kostov, D | 1 |
| Dragnev, N | 1 |
| Patanov, R | 1 |
| Kobakov, G | 1 |
| Zöld, E | 1 |
| Barta, Z | 1 |
| Zeher, M | 1 |
3 other studies available for mebendazole and Carcinoma, Hepatocellular
| Article | Year |
|---|---|
Mebendazole augments sensitivity to sorafenib by targeting MAPK and BCL-2 signalling in n-nitrosodiethylamine-induced murine hepatocellular carcinoma.
Topics: Alanine Transaminase; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cyclin D1; Diethyln | 2019 |
[Hepatocellular carcinoma complicated with echinococcal cyst of the liver].
Topics: Animals; Antinematodal Agents; Carcinoma, Hepatocellular; Cysts; Echinococcosis; Echinococcus; Femal | 2010 |
Hydatid disease of the liver and associated hepatocellular carcinoma.
Topics: Antinematodal Agents; Carcinoma, Hepatocellular; Echinococcosis; Echinococcus granulosus; Fatal Outc | 2005 |